CHELSEA KIZER: Open Payments
NPI 1518588706 · TERRE HAUTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 58 payments from 15 companies in 2025. Trend: 2023 $1,735 · 2024 $1,217 · 2025 $1,217
Food & beverage: $1,127Education: $90
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $271 |
| GlaxoSmithKline, LLC. | 24 | $218 |
| GENZYME CORPORATION | 3 | $145 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $139 |
| Actelion Pharmaceuticals US, Inc. | 2 | $119 |
| Merck Sharp & Dohme LLC | 4 | $93 |
| Amgen Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Vifor Pharma, Inc. | 1 | $30 |
| Viatris Specialty LLC | 1 | $29 |
Products named: FASENRA, DUPIXENT, TRELEGY ELLIPTA, OPSUMIT, NUCALA, OFEV, JASCAYD, WINREVAIR.
Industry payments across IN — which companies pay providers there.
